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The therapeutic effect of inhaled antibiotics on lung infection in CF patients is
dependent on the aerosol deposition achieved in the lungs.
Objectives: To evaluate the inﬂuence of two breathing patterns on pulmonary
aerosol deposition using pharmacokinetic parameters as surrogate for deposition.
Methods: In a randomized, open-label, crossover study pulmonary deposition in
18 adult CF patients is evaluated following inhalation of tobramycin aerosol using
the I-neb nebulizer with TBM (Tidal Breathing Mode) and TIM (Target Inhalation
Mode) breathing patterns. Breathing in TIM forced the patient to inhale in a slow
and deep manner. According to their lung function, patients were categorized in
subgroup 1, 2 or 3 corresponding to FEV1 predicted 59%, 60−79% or 80%.
Blood samples were collected in order to model tobramycin pharmacokinetics.
Results:Mean Cmax and AUC0−24hr were signiﬁcantly increased for TIM compared
to TBM. Inhalation in TIM also resulted in higher mean Cmax and AUC0−24hr for
each subgroup. Mean bioavailability of TIM relative to TBM breathing pattern
(Frel) was 1.53±0.41 and mean Frel in each subgroup was also signiﬁcantly higher
than 1. Subgroup category did not affect the results.
Conclusion: Slow and deep inhalation of aerosolized tobramycin with the I-neb
nebulizer resulted in an estimated 53% higher lung deposition compared to tidal
breathing. This result was independent from lung function category, which suggests
that regardless the disease state, slow and deep inhalation always results in higher
pulmonary aerosol deposition compared to tidal breathing.
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Background: Suboptimal airway clearance technique (ACT) in CF (poor adherence and/or poor
technique) can limit its effectiveness, yet airway clearance has always been “invisible”. The Acapella®
is a common ACT device.
Objectives:
1. Test the feasibility of using an electronic data capture (EDC) system to objectively measure the
use of Acapella® and comparing it against self-report.
2. Use EDC to explore adherence and technique (blow duration and ﬂow rate).
Methods: Unblinded before and after exploratory study using an EDC system among 10 adults with
CF. The EDC system consists of a pressure transducer that records air-ﬂow, date and time. It is
inserted between the mouthpiece and body of the Acapella®. It has a beeper that can be programmed
to provide feedback with an audible beep with every satisfactory blow i.e. breath exhalation with
ﬂow rate 20 L/min that reached the target duration of 3 s.
In the 1st phase, all participants used the EDC without any feedback. In the 2nd phase, the beeper was
turned on to provide immediate feedback when the Acapella® was used. In both phases, participants
reported their estimated daily Acapella® use with a questionnaire. Data collection is ongoing.
Results: Objective EDC suggested that self-report over-estimated adherence. Patients found it difﬁcult
to achieve adequate blows but beeper feedback improved technique. The table presents illustrative
data.
Table: Illustrative results from 1 participant
Participant 1
Phase 1 Phase 2
Follow-up duration, days 4 11
Agreed number of daily blows 20 20
Self-report number of daily blows (% adherence) 20 (100) 20 (100)
Objective (EDC) average number of daily blows (% adherence) 9 (45) 3 (15)
Objective (EDC) total number of blows 36 34
Objective (EDC) total number of satisfactory blows 24 34
Percentage of satisfactory blows (%) 67% 100%
Conclusion: Objective measure of ACT is possible. Feedback may improve the quality of ACT.
Acapella® is a registered trademark of Smiths Medical ASD Inc which supported this study.
